ORIC Pharma Stock Falls Following Early-Stage Prostate Cancer Trial Data

ORIC Pharmaceuticals experienced a drop in its stock value after releasing early-stage trial data for its prostate cancer therapy. The market reacted negatively to the initial results of the clinical study.